Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic avenue for managing metabolic syndromes. These naturally occurring hormones are secreted by the gut in response to meal intake, stimulating insulin production and suppressing glucagon release. GLP-1 agents possess promising therapeutic efficacy in treating type 2 dia